Clinical Trials
8
Trial Phases
4 Phases
Drug Approvals
2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)β’ Click on a phase to view related trials
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2004-03-03
- Last Posted Date
- 2005-11-09
- Lead Sponsor
- Corixa Corporation
- Target Recruit Count
- 506
- Registration Number
- NCT00078598
- Locations
- πΊπΈ
Northside Hospital, Atlanta, Georgia, United States
πΊπΈMedical Oncology/Hematology Associates, Dayton, Ohio, United States
πΊπΈMadigan Army Medical Center, Tacoma, Washington, United States
Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2003-06-19
- Last Posted Date
- 2006-12-06
- Lead Sponsor
- Corixa Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT00062907
- Locations
- πΊπΈ
Cancer Centers of Florida, Ocoee, Florida, United States
πΊπΈMary Crowley Medical Research Clinic, Dallas, Texas, United States
πΊπΈTyler Cancer Center, Tyler, Texas, United States
Expanded Access Study of Iodine-131 Anti-B1 Antibody
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2001-08-20
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Corixa Corporation
- Registration Number
- NCT00022958
- Locations
- πΊπΈ
Central Recruiting Information, South San Francisco, California, United States
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2001-08-20
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Corixa Corporation
- Registration Number
- NCT00022932
- Locations
- πΊπΈ
Rush Medical Center, Chicago, Illinois, United States
πΊπΈTufts New England Medical Center, Boston, Massachusetts, United States
πΊπΈCornell Medical Center, New York, New York, United States
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- First Posted Date
- 2001-08-20
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Corixa Corporation
- Registration Number
- NCT00022945
- Locations
- πΊπΈ
Rush-Presbyterian-St. Lukes Medical Center, Chicago, Illinois, United States
πΊπΈMemorial Sloan-Kettering Cancer Center, New York, New York, United States
πΊπΈHospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Prev
- 1
- 2
- Next